Transactions
2
Insider / Organon & Co.
Ezekowitz Alan
Director at Organon & Co.
- Company
- Organon & Co.
- First filing on record
- June 15, 2026
- Latest trade on record
- June 30, 2026
- SEC filings
- EDGAR ↗
Ezekowitz Alan, Director at Organon & Co., has disclosed 2 transactions in FULC, OGN since June 15, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $240K at the reported prices. The latest was filed July 2, 2026, 2 days after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
2.5d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Ezekowitz Alan reported 2 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 2 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 2 | 49,857 | $240K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| FULC | Other A | June 30, 2026 | July 2, 2026 | 2d | 32,000 | — | — | derivative | Form 4 ↗ | |
| OGN | Other A | June 12, 2026 | June 15, 2026 | 3d | 17,857 | $13 | $240K | derivative | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| July 2, 2026 | Form 4 | 0001193125-26-294680 | 1 | published | EDGAR ↗ |
| June 15, 2026 | Form 4 | 0001628280-26-043224 | 1 | published | EDGAR ↗ |
Other insiders at Organon & Co.
- Sanofi Insider 24 rows
- Holzbaur Lynette SVP and Corporate Controller 18 rows
- Drinane Juliana Papa Interim Head of Mfg & Supply 15 rows
- Morrissey Joseph T. Jr. Interim CEO 15 rows
- WALSH MATTHEW M Chief Financial Officer 15 rows
- COX CARRIE SMITH Director 14 rows
- Falcione Aaron Chief Human Resources Officer 14 rows
- Nisita Vittorio Head of Global Business Svcs 14 rows
- Stahler Rachel A Chief Information Officer 14 rows
- Weaver Kirke Gen. Counsel & Corp. Secy. 14 rows
Everyone on file, with contracts and lobbying under the company's name: Organon & Co..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 2 | 2 | June 15, 2026 | July 2, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.